Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1497

1.

Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.

Li M, Yang Y, Xu C, Wei J, Liu Y, Cun X, Yu Q, Tang X, Yin S, Zhang Z, He Q.

AAPS J. 2019 Jan 11;21(2):18. doi: 10.1208/s12248-018-0289-3.

PMID:
30635795
2.

What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing.

Polasek TM, Rostami-Hodjegan A, Yim DS, Jamei M, Lee H, Kimko H, Kim JK, Nguyen PTT, Darwich AS, Shin JG.

AAPS J. 2019 Jan 9;21(2):17. doi: 10.1208/s12248-018-0286-6.

PMID:
30627939
3.

Survival Prolongation Index as a Novel Metric to Assess Anti-Tumor Activity in Xenograft Models.

Chandra F, Zaks L, Zhu A.

AAPS J. 2019 Jan 9;21(2):16. doi: 10.1208/s12248-018-0284-8.

PMID:
30627814
4.

Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.

Ghassabian S, Gillani TB, Rawling T, Crettol S, Nair PC, Murray M.

AAPS J. 2019 Jan 9;21(2):15. doi: 10.1208/s12248-018-0262-1.

PMID:
30627802
5.
6.

Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.

Liu Q, Absar M, Saluja B, Guo C, Chowdhury B, Lionberger R, Conner DP, Li BV.

AAPS J. 2019 Jan 7;21(2):14. doi: 10.1208/s12248-018-0283-9.

PMID:
30617594
7.

Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin.

Chablani L, Tawde SA, Akalkotkar A, D'Souza MJ.

AAPS J. 2019 Jan 2;21(2):12. doi: 10.1208/s12248-018-0285-7.

PMID:
30604321
8.

Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools.

Goulooze SC, Krekels EHJ, Hankemeier T, Knibbe CAJ.

AAPS J. 2018 Dec 18;21(1):11. doi: 10.1208/s12248-018-0278-6.

PMID:
30565031
9.

Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information.

Detrez I, Schops G, Lefrère J, Tops S, Van Assche G, Vermeire S, Van Moerkercke W, Ferrante M, Gils A.

AAPS J. 2018 Dec 18;21(1):10. doi: 10.1208/s12248-018-0282-x.

PMID:
30564993
10.

Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352A.

Peng K, Wang Y, Siradze K, Erickson R, Fischer SK, Staton TL.

AAPS J. 2018 Dec 13;21(1):9. doi: 10.1208/s12248-018-0280-z.

PMID:
30547287
11.

PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol.

T'jollyn H, Vermeulen A, Van Bocxlaer J.

AAPS J. 2018 Nov 29;21(1):8. doi: 10.1208/s12248-018-0277-7.

PMID:
30498862
12.

The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal.

Mielke J, Innerbichler F, Schiestl M, Ballarini NM, Jones B.

AAPS J. 2018 Nov 27;21(1):7. doi: 10.1208/s12248-018-0275-9.

PMID:
30483892
13.

Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs-a Case Example of Erythropoietin.

An G, Schmidt RL, Mock DM, Veng-Pedersen P, Widness JA.

AAPS J. 2018 Nov 26;21(1):6. doi: 10.1208/s12248-018-0269-7. No abstract available.

PMID:
30478521
14.

Effect of the Plasticizer DEHP in Blood Collection Bags on Human Plasma Fraction Unbound Determination for Alpha-1-Acid Glycoprotein (AAG) Binding Drugs.

Ingram N, Dishinger C, Wood J, Hutzler JM, Smith S, Huskin M.

AAPS J. 2018 Nov 16;21(1):5. doi: 10.1208/s12248-018-0276-8.

PMID:
30446887
15.

Approaches to Resolve False Reporting in Neutralizing Antibody Assays Caused by Reagent Leaching from Affinity Capture Elution Solid Phase.

Xiang Y, Kamerud J, Donley J, Olson K, Caiazzo T, Yeung D, Parng C, Gorovits B.

AAPS J. 2018 Nov 6;21(1):4. doi: 10.1208/s12248-018-0274-x.

PMID:
30402825
16.

In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.

Guan X, Bryniarski MA, Morris ME.

AAPS J. 2018 Nov 5;21(1):3. doi: 10.1208/s12248-018-0261-2.

PMID:
30397860
17.

The Journey to AAPS 2020: a Reflection from Strategic Planning to PharmSci 360.

Polli JW, McCurdy CR, Wurster DE, DeSilva BS, Bak A, Bendayan R, Meibohm B, Templeton AC, Weiser W; AAPS Leadership.

AAPS J. 2018 Nov 3;21(1):2. doi: 10.1208/s12248-018-0273-y. No abstract available.

PMID:
30392015
18.

Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.

Valade E, Kakuda TN, McClure MW, Westland C, Valenzuela B, Ouwerkerk-Mahadevan S, Perez-Ruixo JJ, Ackaert O.

AAPS J. 2018 Oct 24;21(1):1. doi: 10.1208/s12248-018-0272-z.

PMID:
30377854
19.

Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.

Valade E, Valenzuela B, Kakuda TN, Westland C, McClure MW, Ouwerkerk-Mahadevan S, Perez-Ruixo JJ, Ackaert O.

AAPS J. 2018 Oct 22;20(6):111. doi: 10.1208/s12248-018-0271-0.

PMID:
30350297
20.

Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats.

Subudhi BB, Sahu PK, Singh VK, Prusty S.

AAPS J. 2018 Oct 22;20(6):110. doi: 10.1208/s12248-018-0270-1.

PMID:
30350232

Supplemental Content

Loading ...
Support Center